Immunity to melanoma antigens: from self-tolerance to immunotherapy
/in International Publications, Malignant MelanomaVaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma
/in International Publications, Malignant MelanomaTargeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96
/in International Publications, Malignant LymphomaNatural killer cells license dendritic cell cross-presentation of B lymphoma cell–associated antigens
/in International Publications, Malignant LymphomaLong-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells
/in International Publications, Malignant MelanomaDendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients
/in Dendritic Cells, International Publications, Malignant MelanomaVaccine strategies to treat lymphoproliferative disorders
/in Chronic Leukemia, Dendritic Cells, International Publications, Malignant Lymphoma, Multiple Myeloma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer